Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 23:29 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

Once Weekly GLP-1 in Persons With Spinal Cord Injury

ClinicalTrials.gov · NCT03292315 · Registry updated: 2023-03-14

Condition / research focus: Spinal Cord Injuries; Insulin Resistance; Pre Diabetes; Obesity
Sponsor: James J. Peters Veterans Affairs Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2018-10-16. Completion: 2023-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 1MG Injection [Ozempic] (drug)
No Intervention (other)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Kessler Institute for Rehabilitation
West Orange, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

ClinicalTrials.gov · NCT02829502 · Registry updated: 2023-03-03

Condition / research focus: Ischemic Stroke
Sponsor: Christina Kruuse
Countries with listed sites: Denmark
Registry dates and results: Start: 2016-08. Completion: 2023-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Byetta (drug) — also listed as: Exenatide, GLP-1 receptor analogue, GLP-1 receptor agonist
Normosaline (drug) — also listed as: Isotonic saline

Where the study takes place — 1 listed sites

Department of Neurology, Herlev-Gentofte Hospital
Herlev, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT05467514 · Registry updated: 2023-03-02

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: David Sanchez Garcia
Countries with listed sites: Mexico
Registry dates and results: Start: 2022-07-01. Completion: 2023-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Centro Médico Nacional del Noreste Hospital de Especialidades UMAE 25
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of LY3537021 in Healthy Participants

ClinicalTrials.gov · NCT05444569 · Registry updated: 2023-03-01

Condition / research focus: Healthy
Sponsor: Eli Lilly and Company
Countries with listed sites: Singapore
Registry dates and results: Start: 2022-08-08. Completion: 2023-02-24 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LY3537021 (drug)
Liraglutide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT04657939 · Registry updated: 2023-02-27

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: University of Leeds
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-12-01. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Pioglitazone (drug)

Where the study takes place — 1 listed sites

Leeds Teaching Hospitals Trust
Leeds, West Yorkshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

ClinicalTrials.gov · NCT03895697 · Registry updated: 2023-02-21

Condition / research focus: Hypoglycemia; Diabetes Mellitus, Type 1
Sponsor: Zealand Pharma
Countries with listed sites: Canada
Registry dates and results: Start: 2019-03-26. Completion: 2019-07-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

dasiglucagon (drug) — also listed as: ZP4207

Where the study takes place — 1 listed sites

LMC Diabetes & Manna Research
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

ClinicalTrials.gov · NCT02244164 · Registry updated: 2023-02-16

Condition / research focus: Type 2 Diabetes; Incretinomimetics; Pancreas
Sponsor: Erasme University Hospital
Countries with listed sites: Belgium
Registry dates and results: Start: 2014-10. Completion: 2023-02-13 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Incretinomimetics (drug) — also listed as: - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®).
DPP-4 inhibitors (drug) — also listed as: - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®).

Where the study takes place — 1 listed sites

Gastroenterology Department Erasme Hospital
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

ClinicalTrials.gov · NCT02302976 · Registry updated: 2023-02-16

Condition / research focus: Cocaine Dependence
Sponsor: Yale University
Countries with listed sites: United States
Registry dates and results: Start: 2014-11. Completion: 2018-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

cocaine hydrochloride (drug)
exenatide (drug) — also listed as: byetta
placebo (drug)

Where the study takes place — 1 listed sites

Connecticut Mental Health Center
New Haven, Connecticut, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)

ClinicalTrials.gov · NCT05468632 · Registry updated: 2023-02-14

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: North Macedonia
Registry dates and results: Start: 2022-07-05. Completion: 2022-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 17 listed sites

Novo Nordisk Investigational Site
Bitola, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Debar, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
General Hospital Kavadarci, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Gostivar, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kicevo, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kočani, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kumanovo, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Ohrid, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Prilep, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shtip, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Skopje, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Skopje, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Skopje, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Struga, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Stumica, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Tetovo, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Veles, North Macedonia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes

ClinicalTrials.gov · NCT04020445 · Registry updated: 2023-02-13

Condition / research focus: HBA1c; Body Weight; Hypoglycemia
Sponsor: Bekes County Central Hospital
Countries with listed sites: Hungary
Registry dates and results: Start: 2016-01-01. Completion: 2022-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

de-escalation of complex insulin regimens (other)

Where the study takes place — 1 listed sites

Zoltán Taybani
Békéscsaba, Bekes County, Hungary
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Comparison of Ease of Use and Acceptability of Intranasal and Injectable Glucagon Among Providers Administering it to Children or Adolescents With Type 1 Diabetes (BETTER-ING)

ClinicalTrials.gov · NCT05395000 · Registry updated: 2023-02-08

Condition / research focus: Diabetes Mellitus, Type 1; Hypoglycemia
Sponsor: CHU de Quebec-Universite Laval
Countries with listed sites: Canada
Registry dates and results: Start: 2021-03-19. Completion: 2022-09-22 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Videos (behavioral)
Simulation (behavioral)
Interview (behavioral)

Where the study takes place — 1 listed sites

Centre de recherche du CHU de Québec - Université Laval
Québec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT03948347 · Registry updated: 2023-02-06

Condition / research focus: Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus
Sponsor: First Affiliated Hospital of Jinan University
Countries with listed sites: China
Registry dates and results: Start: 2019-06-25. Completion: 2024-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

POSE2.0 With GLP-1 Agonist for Obesity Management

ClinicalTrials.gov · NCT05705388 · Registry updated: 2023-01-30

Condition / research focus: Obesity
Sponsor: Emirates Health Services (EHS)
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-01-16. Completion: 2026-01-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

POSE2.0 Endoscopic Gastric Remodeling (device)
Liraglutide injection (drug)

Where the study takes place — 1 listed sites

Ibrahim Bin Hamad Obaidullah Hospital
Ras al-Khaimah, United Arab Emirates
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Hypoglycemia and Glucagon Response in CF

ClinicalTrials.gov · NCT05700604 · Registry updated: 2023-01-26

Condition / research focus: Cystic Fibrosis; Hypoglycemia; Glucagon Deficiency; Pancreatic Insufficiency
Sponsor: Marmara University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2020-01-01. Completion: 2020-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Marmara University, School of Medicine
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableWithdrawnOBSERVATIONAL

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

ClinicalTrials.gov · NCT05438186 · Registry updated: 2023-01-25

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2022-09-01. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

ClinicalTrials.gov · NCT04545411 · Registry updated: 2023-01-23

Condition / research focus: Type 1 Diabetes
Sponsor: University of California, San Diego
Countries with listed sites: United States
Registry dates and results: Start: 2021-02-22. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dapagliflozin 10 MG [Farxiga] (drug)
REMD-477 (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

UC San Diego Altman Clinical & Translational Research Institute
La Jolla, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

In-market Utilisation of Liraglutide Used for Weight Management in Europe

ClinicalTrials.gov · NCT02967757 · Registry updated: 2023-01-20

Condition / research focus: Metabolism and Nutrition Disorder; Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany · Italy
Registry dates and results: Start: 2016-12-22. Completion: 2019-05-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug)

Where the study takes place — 19 listed sites

Novo Nordisk Investigational Site
Bad Nauheim, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Bünde, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Essen, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Hamburg, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kaiserslautern, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Mainz, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
München, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Münster, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Ulm, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Catania, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Chieti, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Cremona, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Novara, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Pisa, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Potenza, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Roma, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Rome, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Rome, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Siena, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

ClinicalTrials.gov · NCT04093752 · Registry updated: 2023-01-06

Condition / research focus: Type 2 Diabetes
Sponsor: Eli Lilly and Company
Countries with listed sites: Australia · China · India · South Korea
Registry dates and results: Start: 2019-12-09. Completion: 2021-11-24 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Insulin Glargine (drug)

Where the study takes place — 67 listed sites

Paratus Clinical Research Western Sydney
Blacktown, New South Wales, Australia
Site recruitment: Not reported
Paratus Clinical Research Central Coast
Kanwal, New South Wales, Australia
Site recruitment: Not reported
Holdsworth House Medical Practice
Sydney, New South Wales, Australia
Site recruitment: Not reported
Illawarra Shoalhaven Local Health District
Wollongong, New South Wales, Australia
Site recruitment: Not reported
Core Research Group
Milton, Queensland, Australia
Site recruitment: Not reported
Barwon Health - The Geelong Hospital
Geelong, Victoria, Australia
Site recruitment: Not reported
Adelaide Medical Solutions
Woodville South, Australia
Site recruitment: Not reported
Peking University People's Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Huizhou Municipal Central Hospital
Huizhou, Guangdong, China
Site recruitment: Not reported
Cangzhou People's Hospital
Cangzhou, Hebei, China
Site recruitment: Not reported
Hebei Medical University
Hengshui Shi, Hebei, China
Site recruitment: Not reported
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
Site recruitment: Not reported
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Site recruitment: Not reported
The First People's Hospital of Yueyang
Yueyang, Hunan, China
Site recruitment: Not reported
Bao Tou Central Hospital
Baotou, Inner Mongolia, China
Site recruitment: Not reported
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
Site recruitment: Not reported
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Site recruitment: Not reported
The First Hospital of Nanjing
Nanjing, Jiangsu, China
Site recruitment: Not reported
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Site recruitment: Not reported
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Nanjing Medical University - Nanjing Jiangning Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
Site recruitment: Not reported
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Site recruitment: Not reported
Wuxi People's Hospital
Wuxi, Jiangsu, China
Site recruitment: Not reported
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Site recruitment: Not reported
The Third Hospital of Nanchang
Nanchang, Jiangxi, China
Site recruitment: Not reported
The First Hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Not reported
Dalian University - The Affiliated Zhongshan Hospital
Dalian, Liaoning, China
Site recruitment: Not reported
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Site recruitment: Not reported
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Site recruitment: Not reported
Jinan Central Hospital
Jinan, Shandong, China
Site recruitment: Not reported
Qingdao Central Hospital
Qingdao, Shandong, China
Site recruitment: Not reported
Shanghai 6th people's hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
1st affiliated Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Site recruitment: Not reported
The First Affiliated Hospital of Xi'an Medical University
Xi’an, Shanxi, China
Site recruitment: Not reported
West China Hospital Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
Chengdu Fifth People's Hospital
Chengdu, Sichuan, China
Site recruitment: Not reported
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
Chongqing Three Gorges Central Hospital
Wanzhou, Wanzhou, China
Site recruitment: Not reported
Chongqing General Hospital
Chongqing, Yuzhong District, China
Site recruitment: Not reported
Huzhou Central Hospital
Huzhou, Zhejiang, China
Site recruitment: Not reported
Shaoxing People's Hospital
Shaoxing, Zhejiang, China
Site recruitment: Not reported
Beijing Peking Union Medical College Hospital
Beijing, China
Site recruitment: Not reported
Beijing Pinggu District Hospital
Beijing, China
Site recruitment: Not reported
Beijing Tsinghua Changgung Hospital
Beijing, China
Site recruitment: Not reported
Pingxiang People's Hospital
Pingxiang, China
Site recruitment: Not reported
Shanghai Putuo District Center Hospital
Shanghai, China
Site recruitment: Not reported
Tianjin People's Hospital
Tianjin, China
Site recruitment: Not reported
The Fourth People's Hospital of Zigong City
Zigong, China
Site recruitment: Not reported
King Edward Memorial Hospital and Research Center
Mumbai, Maharashtra, India
Site recruitment: Not reported
BSES Municipal General Hsptl
Mumbai, Maharashtra, India
Site recruitment: Not reported
Apollo Gleneagles Hospitals Kolkata
Kolkata, West Bengal, India
Site recruitment: Not reported
Fortis Hospital
Delhi, India
Site recruitment: Not reported
Kyung Hee University Hospital
Seoul, Gangdong-gu, South Korea
Site recruitment: Not reported
Seoul National University Bundang Hospital
Seongnam, Geonggi-do, South Korea
Site recruitment: Not reported
Bucheon St. Mary's Hospital
Bucheon-si, Gyeonggi-do, South Korea
Site recruitment: Not reported
Hanyang University Guri Hospital
Guri-si, Gyeonggido, South Korea
Site recruitment: Not reported
Yonsei University Wonju Severance Christian Hospital
Gangwon-do, Korea, South Korea
Site recruitment: Not reported
Ulsan University Hospital
Ulsan, Korea, South Korea
Site recruitment: Not reported
Inje University Sanggye Paik Hospital
Seoul, Seoul-teukbyeolsi, South Korea
Site recruitment: Not reported
Korea University Anam Hospital
Seoul, Seoul-teukbyeolsi, South Korea
Site recruitment: Not reported
Keimyung University Dongsan Hospital
Daegu, Taegu-Kwangyǒkshi, South Korea
Site recruitment: Not reported
Korea University Ansan Hospital
Ansan-si, South Korea
Site recruitment: Not reported
Severance Hospital
Seoul, South Korea
Site recruitment: Not reported
Asan Medical Center
Seoul, South Korea
Site recruitment: Not reported
Hallym University Kangnam Sacred Heart Hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Thiamine on Serum Glucagon And Reactive Oxygen Species (ROS)

ClinicalTrials.gov · NCT05663164 · Registry updated: 2022-12-23

Condition / research focus: Sepsis; Thiamine Deficiency
Sponsor: Universitas Sumatera Utara
Countries with listed sites: Indonesia
Registry dates and results: Start: 2022-10-01. Completion: 2022-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Vitamin B (drug) — also listed as: Thiamine
Placebo (drug) — also listed as: Normal saline

Where the study takes place — 1 listed sites

Faculty of Medicine Universitas Sumatera Utara
Medan, North Sumatra, Indonesia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

ClinicalTrials.gov · NCT03172494 · Registry updated: 2022-12-14

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: China
Registry dates and results: Start: 2017-05-26. Completion: 2019-07-13 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin degludec/liraglutide (drug)
Insulin degludec (drug)
Liraglutide (drug)

Where the study takes place — 36 listed sites

Novo Nordisk Investigational Site
Hefei, Anhui, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Cangzhou, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Changzhou, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Huai'an, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Huai'an, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Zhenjiang, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanchang, Jiangxi, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Changchun, Jilin, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Dalian, Liaoning, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Yinchuan, Ningxia, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Xi'an, Shaanxi, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Jinan, Shandong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Pudong New District, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kunming, Yunnan, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 23:29 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

Once Weekly GLP-1 in Persons With Spinal Cord Injury

ClinicalTrials.gov · NCT03292315 · Registry updated: 2023-03-14

Condition / research focus: Spinal Cord Injuries; Insulin Resistance; Pre Diabetes; Obesity
Sponsor: James J. Peters Veterans Affairs Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2018-10-16. Completion: 2023-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 1MG Injection [Ozempic] (drug)
No Intervention (other)

Where the study takes place — 1 listed sites

Kessler Institute for Rehabilitation
West Orange, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

ClinicalTrials.gov · NCT02829502 · Registry updated: 2023-03-03

Condition / research focus: Ischemic Stroke
Sponsor: Christina Kruuse
Countries with listed sites: Denmark
Registry dates and results: Start: 2016-08. Completion: 2023-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Byetta (drug) — also listed as: Exenatide, GLP-1 receptor analogue, GLP-1 receptor agonist
Normosaline (drug) — also listed as: Isotonic saline

Where the study takes place — 1 listed sites

Department of Neurology, Herlev-Gentofte Hospital
Herlev, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT05467514 · Registry updated: 2023-03-02

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: David Sanchez Garcia
Countries with listed sites: Mexico
Registry dates and results: Start: 2022-07-01. Completion: 2023-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Centro Médico Nacional del Noreste Hospital de Especialidades UMAE 25
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of LY3537021 in Healthy Participants

ClinicalTrials.gov · NCT05444569 · Registry updated: 2023-03-01

Condition / research focus: Healthy
Sponsor: Eli Lilly and Company
Countries with listed sites: Singapore
Registry dates and results: Start: 2022-08-08. Completion: 2023-02-24 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LY3537021 (drug)
Liraglutide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT04657939 · Registry updated: 2023-02-27

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: University of Leeds
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-12-01. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Pioglitazone (drug)

Where the study takes place — 1 listed sites

Leeds Teaching Hospitals Trust
Leeds, West Yorkshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

ClinicalTrials.gov · NCT03895697 · Registry updated: 2023-02-21

Condition / research focus: Hypoglycemia; Diabetes Mellitus, Type 1
Sponsor: Zealand Pharma
Countries with listed sites: Canada
Registry dates and results: Start: 2019-03-26. Completion: 2019-07-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

dasiglucagon (drug) — also listed as: ZP4207

Where the study takes place — 1 listed sites

LMC Diabetes & Manna Research
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

ClinicalTrials.gov · NCT02244164 · Registry updated: 2023-02-16

Condition / research focus: Type 2 Diabetes; Incretinomimetics; Pancreas
Sponsor: Erasme University Hospital
Countries with listed sites: Belgium
Registry dates and results: Start: 2014-10. Completion: 2023-02-13 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Incretinomimetics (drug) — also listed as: - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®).
DPP-4 inhibitors (drug) — also listed as: - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®).

Where the study takes place — 1 listed sites

Gastroenterology Department Erasme Hospital
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

ClinicalTrials.gov · NCT02302976 · Registry updated: 2023-02-16

Condition / research focus: Cocaine Dependence
Sponsor: Yale University
Countries with listed sites: United States
Registry dates and results: Start: 2014-11. Completion: 2018-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

cocaine hydrochloride (drug)
exenatide (drug) — also listed as: byetta
placebo (drug)

Where the study takes place — 1 listed sites

Connecticut Mental Health Center
New Haven, Connecticut, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)

ClinicalTrials.gov · NCT05468632 · Registry updated: 2023-02-14

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: North Macedonia
Registry dates and results: Start: 2022-07-05. Completion: 2022-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 17 listed sites

Novo Nordisk Investigational Site
Bitola, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Debar, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
General Hospital Kavadarci, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Gostivar, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kicevo, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kočani, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kumanovo, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Ohrid, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Prilep, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shtip, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Skopje, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Skopje, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Skopje, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Struga, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Stumica, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Tetovo, North Macedonia
Site recruitment: Not reported
Novo Nordisk Investigational Site
Veles, North Macedonia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes

ClinicalTrials.gov · NCT04020445 · Registry updated: 2023-02-13

Condition / research focus: HBA1c; Body Weight; Hypoglycemia
Sponsor: Bekes County Central Hospital
Countries with listed sites: Hungary
Registry dates and results: Start: 2016-01-01. Completion: 2022-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

de-escalation of complex insulin regimens (other)

Where the study takes place — 1 listed sites

Zoltán Taybani
Békéscsaba, Bekes County, Hungary
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Comparison of Ease of Use and Acceptability of Intranasal and Injectable Glucagon Among Providers Administering it to Children or Adolescents With Type 1 Diabetes (BETTER-ING)

ClinicalTrials.gov · NCT05395000 · Registry updated: 2023-02-08

Condition / research focus: Diabetes Mellitus, Type 1; Hypoglycemia
Sponsor: CHU de Quebec-Universite Laval
Countries with listed sites: Canada
Registry dates and results: Start: 2021-03-19. Completion: 2022-09-22 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Videos (behavioral)
Simulation (behavioral)
Interview (behavioral)

Where the study takes place — 1 listed sites

Centre de recherche du CHU de Québec - Université Laval
Québec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT03948347 · Registry updated: 2023-02-06

Condition / research focus: Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus
Sponsor: First Affiliated Hospital of Jinan University
Countries with listed sites: China
Registry dates and results: Start: 2019-06-25. Completion: 2024-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

POSE2.0 With GLP-1 Agonist for Obesity Management

ClinicalTrials.gov · NCT05705388 · Registry updated: 2023-01-30

Condition / research focus: Obesity
Sponsor: Emirates Health Services (EHS)
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-01-16. Completion: 2026-01-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

POSE2.0 Endoscopic Gastric Remodeling (device)
Liraglutide injection (drug)

Where the study takes place — 1 listed sites

Ibrahim Bin Hamad Obaidullah Hospital
Ras al-Khaimah, United Arab Emirates
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Hypoglycemia and Glucagon Response in CF

ClinicalTrials.gov · NCT05700604 · Registry updated: 2023-01-26

Condition / research focus: Cystic Fibrosis; Hypoglycemia; Glucagon Deficiency; Pancreatic Insufficiency
Sponsor: Marmara University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2020-01-01. Completion: 2020-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Marmara University, School of Medicine
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableWithdrawnOBSERVATIONAL

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

ClinicalTrials.gov · NCT05438186 · Registry updated: 2023-01-25

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2022-09-01. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

ClinicalTrials.gov · NCT04545411 · Registry updated: 2023-01-23

Condition / research focus: Type 1 Diabetes
Sponsor: University of California, San Diego
Countries with listed sites: United States
Registry dates and results: Start: 2021-02-22. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dapagliflozin 10 MG [Farxiga] (drug)
REMD-477 (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

UC San Diego Altman Clinical & Translational Research Institute
La Jolla, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

In-market Utilisation of Liraglutide Used for Weight Management in Europe

ClinicalTrials.gov · NCT02967757 · Registry updated: 2023-01-20

Condition / research focus: Metabolism and Nutrition Disorder; Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany · Italy
Registry dates and results: Start: 2016-12-22. Completion: 2019-05-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug)

Where the study takes place — 19 listed sites

Novo Nordisk Investigational Site
Bad Nauheim, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Bünde, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Essen, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Hamburg, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kaiserslautern, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Mainz, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
München, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Münster, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Ulm, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Catania, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Chieti, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Cremona, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Novara, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Pisa, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Potenza, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Roma, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Rome, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Rome, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Siena, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

ClinicalTrials.gov · NCT04093752 · Registry updated: 2023-01-06

Condition / research focus: Type 2 Diabetes
Sponsor: Eli Lilly and Company
Countries with listed sites: Australia · China · India · South Korea
Registry dates and results: Start: 2019-12-09. Completion: 2021-11-24 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Insulin Glargine (drug)

Where the study takes place — 67 listed sites

Paratus Clinical Research Western Sydney
Blacktown, New South Wales, Australia
Site recruitment: Not reported
Paratus Clinical Research Central Coast
Kanwal, New South Wales, Australia
Site recruitment: Not reported
Holdsworth House Medical Practice
Sydney, New South Wales, Australia
Site recruitment: Not reported
Illawarra Shoalhaven Local Health District
Wollongong, New South Wales, Australia
Site recruitment: Not reported
Core Research Group
Milton, Queensland, Australia
Site recruitment: Not reported
Barwon Health - The Geelong Hospital
Geelong, Victoria, Australia
Site recruitment: Not reported
Adelaide Medical Solutions
Woodville South, Australia
Site recruitment: Not reported
Peking University People's Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Huizhou Municipal Central Hospital
Huizhou, Guangdong, China
Site recruitment: Not reported
Cangzhou People's Hospital
Cangzhou, Hebei, China
Site recruitment: Not reported
Hebei Medical University
Hengshui Shi, Hebei, China
Site recruitment: Not reported
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
Site recruitment: Not reported
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Site recruitment: Not reported
The First People's Hospital of Yueyang
Yueyang, Hunan, China
Site recruitment: Not reported
Bao Tou Central Hospital
Baotou, Inner Mongolia, China
Site recruitment: Not reported
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
Site recruitment: Not reported
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Site recruitment: Not reported
The First Hospital of Nanjing
Nanjing, Jiangsu, China
Site recruitment: Not reported
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China
Site recruitment: Not reported
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Nanjing Medical University - Nanjing Jiangning Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
Site recruitment: Not reported
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Site recruitment: Not reported
Wuxi People's Hospital
Wuxi, Jiangsu, China
Site recruitment: Not reported
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Site recruitment: Not reported
The Third Hospital of Nanchang
Nanchang, Jiangxi, China
Site recruitment: Not reported
The First Hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Not reported
Dalian University - The Affiliated Zhongshan Hospital
Dalian, Liaoning, China
Site recruitment: Not reported
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Site recruitment: Not reported
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Site recruitment: Not reported
Jinan Central Hospital
Jinan, Shandong, China
Site recruitment: Not reported
Qingdao Central Hospital
Qingdao, Shandong, China
Site recruitment: Not reported
Shanghai 6th people's hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
1st affiliated Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Site recruitment: Not reported
The First Affiliated Hospital of Xi'an Medical University
Xi’an, Shanxi, China
Site recruitment: Not reported
West China Hospital Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
Chengdu Fifth People's Hospital
Chengdu, Sichuan, China
Site recruitment: Not reported
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
Chongqing Three Gorges Central Hospital
Wanzhou, Wanzhou, China
Site recruitment: Not reported
Chongqing General Hospital
Chongqing, Yuzhong District, China
Site recruitment: Not reported
Huzhou Central Hospital
Huzhou, Zhejiang, China
Site recruitment: Not reported
Shaoxing People's Hospital
Shaoxing, Zhejiang, China
Site recruitment: Not reported
Beijing Peking Union Medical College Hospital
Beijing, China
Site recruitment: Not reported
Beijing Pinggu District Hospital
Beijing, China
Site recruitment: Not reported
Beijing Tsinghua Changgung Hospital
Beijing, China
Site recruitment: Not reported
Pingxiang People's Hospital
Pingxiang, China
Site recruitment: Not reported
Shanghai Putuo District Center Hospital
Shanghai, China
Site recruitment: Not reported
Tianjin People's Hospital
Tianjin, China
Site recruitment: Not reported
The Fourth People's Hospital of Zigong City
Zigong, China
Site recruitment: Not reported
King Edward Memorial Hospital and Research Center
Mumbai, Maharashtra, India
Site recruitment: Not reported
BSES Municipal General Hsptl
Mumbai, Maharashtra, India
Site recruitment: Not reported
Apollo Gleneagles Hospitals Kolkata
Kolkata, West Bengal, India
Site recruitment: Not reported
Fortis Hospital
Delhi, India
Site recruitment: Not reported
Kyung Hee University Hospital
Seoul, Gangdong-gu, South Korea
Site recruitment: Not reported
Seoul National University Bundang Hospital
Seongnam, Geonggi-do, South Korea
Site recruitment: Not reported
Bucheon St. Mary's Hospital
Bucheon-si, Gyeonggi-do, South Korea
Site recruitment: Not reported
Hanyang University Guri Hospital
Guri-si, Gyeonggido, South Korea
Site recruitment: Not reported
Yonsei University Wonju Severance Christian Hospital
Gangwon-do, Korea, South Korea
Site recruitment: Not reported
Ulsan University Hospital
Ulsan, Korea, South Korea
Site recruitment: Not reported
Inje University Sanggye Paik Hospital
Seoul, Seoul-teukbyeolsi, South Korea
Site recruitment: Not reported
Korea University Anam Hospital
Seoul, Seoul-teukbyeolsi, South Korea
Site recruitment: Not reported
Keimyung University Dongsan Hospital
Daegu, Taegu-Kwangyǒkshi, South Korea
Site recruitment: Not reported
Korea University Ansan Hospital
Ansan-si, South Korea
Site recruitment: Not reported
Severance Hospital
Seoul, South Korea
Site recruitment: Not reported
Asan Medical Center
Seoul, South Korea
Site recruitment: Not reported
Hallym University Kangnam Sacred Heart Hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Thiamine on Serum Glucagon And Reactive Oxygen Species (ROS)

ClinicalTrials.gov · NCT05663164 · Registry updated: 2022-12-23

Condition / research focus: Sepsis; Thiamine Deficiency
Sponsor: Universitas Sumatera Utara
Countries with listed sites: Indonesia
Registry dates and results: Start: 2022-10-01. Completion: 2022-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Vitamin B (drug) — also listed as: Thiamine
Placebo (drug) — also listed as: Normal saline

Where the study takes place — 1 listed sites

Faculty of Medicine Universitas Sumatera Utara
Medan, North Sumatra, Indonesia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

ClinicalTrials.gov · NCT03172494 · Registry updated: 2022-12-14

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: China
Registry dates and results: Start: 2017-05-26. Completion: 2019-07-13 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin degludec/liraglutide (drug)
Insulin degludec (drug)
Liraglutide (drug)

Where the study takes place — 36 listed sites

Novo Nordisk Investigational Site
Hefei, Anhui, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Cangzhou, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Changzhou, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Huai'an, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Huai'an, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Zhenjiang, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanchang, Jiangxi, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Changchun, Jilin, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Dalian, Liaoning, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Yinchuan, Ningxia, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Xi'an, Shaanxi, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Jinan, Shandong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Pudong New District, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kunming, Yunnan, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →